Key result
ACEIs linked to ~18% lower odds of COVID-19 diagnosis with no increased mortality risk.
Why the study?
Antihypertensive drugs have been implicated in COVID-19 susceptibility and severity, but estimated associations may be susceptible to bias.
Do antihypertensive medications increase the risk of COVID-19 diagnosis or mortality in a population-based cohort?
Population
16,866 COVID-19 cases and 70,137 matched controls from the UK Clinical Practice Research Datalink
Design
Population-based case-control study
Authors
Loading...
No increased COVID-19 risk with antihypertensives after adjustment; leaves open residual confounding in observational data.
Case-Control (n=87,003)
Do antihypertensive medications increase the risk of COVID-19 diagnosis or mortality in a population-based cohort?
Odds Ratio: 0.82 (95% CI 0.77–0.88)
Antihypertensive therapy, including ACE inhibitors and ARBs, is not associated with an increased risk of COVID-19 diagnosis or mortality, supporting their continued use during the pandemic.
Rezel‐Potts et al. (2021) conducted a case-control in COVID-19 (n=87,003). Angiotensin-converting enzyme inhibitors (ACEIs) vs. Matched controls / unexposed was evaluated on COVID-19 diagnosis (AOR 0.82, 95% CI 0.77-0.88). Angiotensin-converting enzyme inhibitors were associated with lower odds of COVID-19 diagnosis (AOR 0.82; 95% CI 0.77-0.88), with no evidence of increased mortality risk.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: